Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: Experience of the European Lung Cancer Working Party

VIP-E chemotherapy is an effective induction therapy for SCLC. Compared with traditional protocols such as ACO or carboplatin/etoposide, response rates are slightly improved, while survival is not different. In the LD SCLC subgroup, high-dose chemotherapy improved response rates and survival, especially for patients in surgical CR prior to high-dose therapy. In ED SCLC, however, higher response-rates did not translate into improved survival. Selected LD-SCLC patients with good partial or complete remissions after prior therapy may benefit from HDC and PBSCT.

show abstract

Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer

Gogas

Lofts²,

Evans³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary To assess the efficacy and toxicity of an outpatient combination chemotherapy in small-cell lung cancer (SCLC), we 10.5 months (range 0.5-70 +) and 7 months (range 0.5-24) in those with extensive disease. Improvement of symptoms occurred in 79% of patients with shortness of breath, 80% with cough, 81% with haemoptysis and 68% with pain. In 19 patients an increase in body weight was noted. Major (WHO grade 3/4) toxicities were neutropenia in 13 (18.5%) patients, alopecia in 33 (47.1%) patients, mucositis in 15 (21.4%) patients, anorexia in eight patients (11.4%), nausea and vomiting in six patients (8.5%) and diarrhoea in 4 (5.7%) patients. In conclusion, EE is an active and well-tolerated outpatient regimen in the treatment of SCLC. The survival data in this unselected group of patients were disappointing and the possible explanations for this are discussed.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: Experience of the European Lung Cancer Working Party

Cited by 6 publications

References 0 publications

Quelles questions dans les cancers bronchiques à petites cellules ? comment la recherche doit-elle s’orienter ?

Quelles questions dans les cancers bronchiques à petites cellules ? comment la recherche doit-elle s’orienter ?

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer

Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer

Contact Info

Product

Resources

About